Egyszerű nézet

dc.contributor.author Weiszhar, Zsóka
dc.contributor.author Czucz J
dc.contributor.author Revesz C
dc.contributor.author Rosivall, László
dc.contributor.author Szebeni, János
dc.contributor.author Rozsnyay Z
dc.date.accessioned 2017-01-16T10:14:22Z
dc.date.available 2017-01-16T10:14:22Z
dc.date.issued 2012
dc.identifier 84856245990
dc.identifier.citation pagination=492-498; journalVolume=45; journalIssueNumber=4; journalTitle=EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/3935
dc.identifier.uri doi:10.1016/j.ejps.2011.09.016
dc.description.abstract Immunosafety analysis of pharmaceutical surfactants is an important step in understanding the complex mechanisms by which they induce side effects in susceptible patients. This paper provides experimental evidences that polyethoxylated surfactants, Cremophor-EL and Tween-80, also known as Polysorbate-80, activate the complement system in vitro, in normal human serum and plasma. They appeared to be more efficient reactogens than their structural homolog, Tween-20. Cremophor-EL and Tween-80 promoted the generation of biologically active complement products, C3a, C5a and C5b-9. Consistently, Paclitaxel and Taxotere (Docetaxel), pharmaceuticals formulated in Cremophor-EL and Tween-80, activated the complement system in similar extent. Moreover, comparison of serum reactivity against the drug-loaded and drug-free formulations exhibited a significant linear correlation. Taken together, these results are consistent with the hypothesis that therapeutic side effects, such as acute hypersensitivity and systemic immunostimulation, caused by intravenous nanomedicines containing polyethoxylated detergents such as Cremophor-EL and Tween-80, can be attributed to complement activation-derived inflammatory mediators.
dc.relation.ispartof urn:issn:0928-0987
dc.title Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20
dc.type Journal Article
dc.date.updated 2016-12-09T11:10:50Z
dc.language.rfc3066 en
dc.identifier.mtmt 1826359
dc.identifier.wos 000300861700014
dc.identifier.pubmed 21963457
dc.contributor.department SE/AOK/I/Kórélettani Intézet
dc.contributor.department SE/AOK/K/ISZGYK/MTA-SE Gyermekgyógyászati és Nephrológiai Kutatócsoport
dc.contributor.department SE/AOK/K/Pulmonológiai Klinika
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote CI: Copyright (c) 2011 Elsevier B.V. All rights reserved. : Federation for Pharmaceutical Sciences


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet